Skip to content
See how we’re building brain interfaces to enable silent speech

Neuralink updates

Jan 28, 2026Company

Two Years of Telepathy

Announcing 21 Neuralink participants.

Dec 9, 2025Company

Welcome, David McMullen!

We’re thrilled to welcome David McMullen to Neuralink.

Dec 3, 2025Company

Neuralink Overview, Fall 2025 (opens in a new tab)

DJ and our recruiting team visited several schools to provide an overview of Neuralink, including recent progress updates and an outline for the company’s path ahead.

Jul 31, 2025Company

GB-PRIME Study Launch

We are excited to announce that we are launching the GB-PRIME study across two sites in Great Britain!

Jun 27, 2025Company

Neuralink Update, Summer 2025 (opens in a new tab)

A technical progress update from the Neuralink team.

Jun 2, 2025Company

Neuralink raises $650M Series E

Our $650M Series E will expand patient access to our technology and push the boundaries of what’s possible with brain interfaces.

May 1, 2025Company

Neuralink Receives Breakthrough Device Designation for Speech

We've received Breakthrough Device Designation from the FDA to help restore communication for individuals with severe speech impairment.

Feb 5, 2025Company

A Year of Telepathy

Over the past year, three people with paralysis have received Neuralink implants. This blog post explores how each person is using Telepathy in everyday life.

Nov 24, 2024Company

CONVOY Study Launch

We’re excited to announce the launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm.

Nov 20, 2024Company

CAN-PRIME Study Launch

We are excited to announce that we have received approval from Health Canada to launch the CAN-PRIME Study, our first international trial!

Sep 17, 2024Company

Neuralink Receives Breakthrough Device Designation for Blindsight

We are excited to announce that we have received Breakthrough Device Designation from the FDA for Blindsight! For individuals with vision impairment.

Aug 21, 2024Company

PRIME Study Progress Update — Second Participant

Our technology is enabling our second PRIME Study participant to play video games and use CAD software. This post shares updates on his experience.

Jul 10, 2024Company

Neuralink Update (opens in a new tab)

The Neuralink team shares an update on the progress of the first Neuralink study participant and changes made in advance of the second participant.

May 8, 2024Company

PRIME Study Progress Update — User Experience

We’ve just passed 100 days since the first participant in our clinical trial received his Neuralink implant. Read our latest progress update.

Apr 12, 2024Company

PRIME Study Progress Update

In January, we conducted the first human implantation of our brain-computer interface. This blog post shares a high-level snapshot of where we are as a company.

Mar 24, 2024Company

Neuralink’s Patient Registry Opens to Canada

In Neuralink's first international expansion, our Patient Registry is now accepting applications from Canadian residents.

Mar 15, 2024Company

Understanding Preclinical Research at Neuralink

Become acquainted with the Preclinical Team, which is responsible for the design, conduct, documentation, analysis, and reporting of preclinical studies.

Sep 19, 2023Company

Neuralink’s First-in-Human Clinical Trial is Open for Recruitment

We are happy to announce that we've received approval to begin recruitment for our first-in-human trial at our first hospital site.

Aug 7, 2023Company

Neuralink Raises $280M Series D

We’re happy to announce our $280M Series D round led by Founders Fund. We’re extremely excited about this next chapter at Neuralink.

May 8, 2023Company

The Role of the Institutional Animal Care and Use Committee

We explore the functions of Neuralink’s Institutional Animal Care and Use Committee (IACUC) and its role in promoting refinement, reduction, and replacement.

Apr 7, 2023Company

Environmental Enrichment

In our second blog on refinement, we highlight our methodology to ensure that we provide an enriching environment and experience to animals within our care.

Dec 17, 2022Company

Announcing Neuralink's Patient Registry

We’ve launched a Patient Registry to learn more about individuals who may be interested in enrolling in future Neuralink clinical trials.

Nov 30, 2022Company

Husbandry Refinement

The first episode of our Refinement Series will look at how we evaluate the well-being of an animal as it pertains to housing, food, and water.

Nov 30, 2022Company

Neuralink Show and Tell, Fall 2022 (opens in a new tab)

A technical progress update from the Neuralink team.

Nov 20, 2022Company

Championing the 3 Rs

We hope you will take this opportunity to learn alongside us as we dive into the complex world of ensuring animal well-being in a research setting.

Feb 14, 2022Company

Neuralink's Commitment to Animal Welfare

Animals at Neuralink are respected and honored by our team. In this blog post, we provide an accurate statement of Neuralink’s commitment to animal welfare.

Jul 29, 2021Company

Series C Funding Round Announcement

Neuralink is pleased to announce our Series C funding round of $205 million. Neuralink is developing brain-computer interfaces to treat brain related ailments.

Aug 28, 2020Company

Neuralink Progress Update, Summer 2020 (opens in a new tab)

A technical progress update from the Neuralink team.

Jul 16, 2019Company

Neuralink Launch Event (opens in a new tab)

Introducing Neuralink.